AIMS/HYPOTHESIS
Obesity drives cardiometabolic dysfunction and increases cardiovascular risk, with excess fat mass and impaired body composition playing a key role in metabolic outcomes. This clinical study aimed to evaluate the real-world effectiveness (RWE) of tirzepatide on body weight, body composition, and metabol...
Davide Brancato, V. Maggio, Francesca Vaccaro et al.· Journal of diabetes and its...· 0 citations
Background/Objectives: Overweight and obesity are major drivers of cardiometabolic dysfunction and increase the risk of type 2 diabetes (T2DM)and cardiovascular disease. Although lifestyle intervention remains the cornerstone of treatment, complementary strategies may provide additional benefits. The effects of Glucoer...
V. Maggio, Francesca Vaccaro, Elena Muratore et al.· Journal of Clinical Medicine· 0 citations
The evidence supports an integrated and personalized management strategy targeting both metabolic and vascular abnormalities to reduce cardiovascular risk and improve long-term clinical outcomes in individuals with obesity.
R. V. Giglio, S. Stanković, Angelo M. Patti et al.· International Journal of Mol...· 0 citations
The principles of harmonized reporting for Alzheimer’s disease biomarkers and a structured framework for standardized clinical neurochemistry reports are discussed and a structured framework for standardized clinical neurochemistry reports is proposed.
L. Agnello, Andrea Pilotto, L. Gaetani et al.· Clinical Chemistry and Labor...· 0 citations
Blood sTREM2 does not directly mirror central nervous system microglial activation but may reflect peripheral immune dynamics, warranting further investigation into its role as a biomarker of systemic immune dysfunction in neurodegenerative diseases.
L. Agnello, C. Gambino, Giuseppe Salemi et al.· European Journal of Neurosci...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.